Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Bertram Glass, Bettina Altmann, Matthias Stelljes, Georg Lenz, Julia Marx, Justin Hasenkamp, Frank P. Kroschinsky, Anna Ossami Saidy, Peter Dreger, Lutz Peter Hermann Mueller, Inken Hilgendorf, Gerald Illerhaus, Guido Kobbe, Roland Schroers, Katrin Linke, Carsta Koehler, Norbert Schmitz, Marita Ziepert, Pearl van Heteren

Blood (2023) 142 (Supplement 1): 231.

https://doi.org/10.1182/blood-2023-173179

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

Journal Articles

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Blood (2023) 142 (Supplement 1): 191.

https://doi.org/10.1182/blood-2023-184611

Published: 2023

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138412

Published: 2020

Journal Articles

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Jonas Matthias Jabs, Viola Poeschel, MD, Martin Sökler, MD, Kerstin Habersang, MD, Rolf Mahlberg, MD, Ulrich Keller, Professor Dr, Heinz-Gert Hoeffkes, Professor Dr, Andreas Rank, PD Dr, Andreas Viardot, Professor Dr, Andreas Neubauer, Professor Dr, Marita Ziepert, PhD, Bettina Altmann, PhD, Stephan Stilgenbauer, MD, Michael Pfreundschuh, Professor Dr, Gerhard Held, Professor Dr, Joerg Thomas Bittenbring, MD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134944

Published: 2020

Journal Articles

Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Lorenz Thurner, MD, Viola Poeschel, MD, Bettina Altmann, PhD, Herve Tilly, MD PhD, Marc Andre, MD, Marie Maerevoet, MD, Thomas Weber, MD, Joerg Hoffmann, MD, Martin Dreyling, MD, Herve Maisonneuve, MD, Andrea Kerkhoff, MD, Steven Le Gouill, MD PhD, Stephan Stilgenbauer, MD, Marita Ziepert, PhD, Roch Houot, MDPhD, Corinne Haioun, MDPhD, Gerhard Held, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-139459

Published: 2020

Journal Articles

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136941

Published: 2020

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma

Dominic Kaddu-Mulindwa, MD, Bettina Altmann, PhD, Gerhard Held, MD, Marita Ziepert, PhD, Karin Menhart, MD, Jirka Grosse, MD, Stephanie Angel, Stephan Stilgenbauer, Michael Pfreundschuh, MD, Ken Herrmann, MD PhD, Ulrich Duehrsen, MD, Andreas Hüttmann, MD, Francesco Barbato, Dirk Hellwig, Viola Poeschel, MD

Blood (2019) 134 (Supplement_1): 2892.

https://doi.org/10.1182/blood-2019-128896

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD

Blood (2018) 132 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2018-99-112076

Published: 2018

Journal Articles

Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL>60 Trial of the Dshnhl

Blood (2017) 130 (Supplement 1): 1549.

https://doi.org/10.1182/blood.V130.Suppl_1.1549.1549

Published: 2017

NARROW

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only